目的 研究華蟾素注射液輔助治療前列腺癌的臨床療效。方法 收集2015年1月—2017年2月襄陽市中心醫(yī)院（湖北文理學(xué)院附屬醫(yī)院）腫瘤科收治的前列腺癌患者110例，隨機(jī)分為對(duì)照組和治療組，每組各55例。對(duì)照組患者給予相應(yīng)的放化療治療。治療組在放化療開始時(shí)即靜脈滴注華蟾素注射液，10～20 mL稀釋于5%葡萄糖注射液250 mL中，連續(xù)用藥6 d，停藥1 d。連續(xù)用藥3周為1個(gè)療程，共治療4個(gè)療程。觀察兩組的臨床療效，比較兩組治療前后血清前列腺特異抗原（PSA）水平和毒副反應(yīng)。結(jié)果 治療后，對(duì)照組客觀緩解率（ORR）是69.09%，臨床獲益率（CBR）是85.45%；治療組ORR是89.09%，CBR是96.36%，兩組ORR、CBR比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者血清PSA水平均顯著降低，同組治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組血清PSA水平顯著低于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療組患者白細(xì)胞減少、惡心嘔吐的發(fā)生率明顯低于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 華蟾素注射液輔助治療前列腺癌臨床療效確切，能顯著降低血清PSA水平，減少患者白細(xì)胞降低和惡心嘔吐的發(fā)生率，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the efficacy of Cinobufacin Injection in treatment of prostate cancer. Methods Patients (110 cases) with prostate cancer in Oncology Department of Xiangyang Central Hospital (the Affiliated Hospital of Hubei University of Arts and Science) from January 2015 to February 2017 were randomly divided into control (55 cases) and treatment (55 cases) groups. Patients in the control group were treated with radiotherapy and chemotherapy. Patients in the treatment group were iv administered with Cinobufacin Injection, 10-20 mL was diluted in 5% glucose injection 250 mL, continuous treatment for 6 d, stop 1 d. Three weeks were 1 course of treatment and they were treated for 4 courses. After treatment, the clinical efficacy was evaluated, and the serum prostate specific antigen (PSA) level and the toxic side reaction in two groups were compared. Results After treatment, the ORR and CBR in the control group were 69.09% and 85.45%, and the ORR and CBR in the treatment group were 89.09% and 96.36%, and there were differences between two groups (P < 0.05). After treatment, PSA in two groups were significantly decreased, and there were differences in the same group (P < 0.05). After treatment, PSA in the treatment group was lower than that in the control group, and there were differences between two groups (P < 0.05). The leukocyte reduction incidence, and nausea and vomiting incidence in the treatment group was significantly lower than those in the control group, and there were differences between two groups (P < 0.05). Conclusion Cinobufacin Injection has significant clinical effect in treatment of prostate cancer, and can significantly reduce the serum PSA level, and also can reduce the incidence of leukocyte reduction and nausea and vomiting, which has a certain clinical application value.